What Panodin-SR Treats: Main Uses and Benefits

Panodin-SR generally is used across therapeutic domains where additional symptomatic support is needed to address discomfort and inflammation, particularly in the musculoskeletal system. This medication is commonly used to help with challenging symptoms associated with chronic and acute inflammatory conditions.

The medication may be relevant for easing symptoms in chronic conditions like Osteoarthritis and Rheumatoid Arthritis, and it is also applied for short-term assistance during acute episodes such as gouty arthritis, tendinitis, and pain following traumatic injury. It plays a role in managing symptom clusters that may become intense or disruptive, focusing on pain, swelling, and stiffness.

By assisting with the management of these pronounced manifestations, Panodin-SR may support patients during episodes of heightened discomfort and contributes to easing the overall symptom load. The use of the sustained-release formulation is relevant when patients require relief that may be long-acting, which may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Pain and Inflammation
Typical Use: Applied when symptoms create noticeable physiological strain in conditions presenting with acute or recurrent inflammatory manifestations.
Main Benefit: Contributes to improved comfort during periods of heightened symptoms by helping to moderate symptoms that interfere with daily functioning.

Regulatory References

1. NIH DailyMed official information on Etodolac Extended-Release

The eligibility for using Panodin-SR (Etodolac extended-release) is strictly defined by government regulatory documents, which establish groups who are permitted, restricted, or absolutely prohibited from using the medicine.

Populations Explicitly Contraindicated

Use is contraindicated and must not occur for the following populations:

• Patients with a known hypersensitivity to Etodolac or a history of allergic-type reactions (including asthma or hives) after taking aspirin or other NSAIDs.
• Treatment of pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
• Patients with active gastrointestinal bleeding, ulceration, or perforation.
• Pregnant women at or after 30 weeks of gestation (late-stage pregnancy).

Age-Related and Conditional Eligibility

Classification	Population Rule
Pediatric Use	Safety and effectiveness are not established for children younger than 6 years.
Older Adults	Patients over 65 years must use with caution due to greater risk for serious gastrointestinal and renal adverse events.
Organ Impairment	Use is not recommended in patients with severe renal impairment or severe hepatic failure.
Pregnancy	Use at 20 weeks gestation or later is restricted; use in lactation is not recommended as excretion into human milk is unknown.

The interaction profile for Panodin-SR (Etodolac) is formally defined by its potential to affect the plasma exposure of co-administered medicines and increase specific risks, all of which are documented in official regulatory materials.

Interaction Type	Interacting Substances / Conditions	Official Restriction or Outcome
Contraindicated	CABG Surgery (peri-operative pain)	Absolute prohibition of use.
	Aspirin or other NSAIDs	Contraindicated if there is a history of allergic-type reactions.
Exposure Alterations	Methotrexate, Lithium	Decreased elimination, leading to elevated plasma levels of the co-administered drug.
	Antacids	Officially documented reduction in peak concentration (Cmax) of Etodolac.
Pharmacodynamic Risk	Anticoagulants (e.g., Warfarin)	Synergistic effect on GI bleeding risk.
	Ciclosporin, Tacrolimus	Increased risk of nephrotoxicity.
	Diuretics, Anti-hypertensives	Potential to diminish the effectiveness of these agents.

Regulatory documentation notes mandatory timing separation: Panodin-SR should not be administered for 8–12 days following Mifepristone use. Co-administration with food is formally documented to reduce the peak plasma concentration (Cmax) of Etodolac, though the total amount absorbed remains unchanged. Additionally, elderly patients are officially documented to be at greater risk for serious gastrointestinal events when Etodolac is combined with interacting substances.

Preferential Inhibition of the COX-2 Enzyme

Panodin-SR acts by preferentially inhibiting the Cyclooxygenase-2 ( COX-2) enzyme, the primary molecular target responsible for synthesizing pro-inflammatory mediators from Arachidonic Acid. This targeted blockade restricts the production of chemical messengers like Prostaglandin E2 ( PGE2), focusing the mechanism on inflammatory signaling pathways.

---

Modifying Nociceptive and Thermoregulatory Cascades

The reduction of PGE2 initiates a cascade that modifies both peripheral nociceptive signaling and central thermoregulation. The mechanism alters the threshold for activation of peripheral nociceptors while simultaneously acting within the hypothalamic center to alter the body temperature set point when elevated.

---

Sustaining the Inhibition Mechanism

The Sustained-Release (SR) formulation is an engineered delivery mechanism designed to extend the time over which the COX-2 inhibition occurs. By maintaining stable and consistent concentrations of the active component over an extended period, the SR profile ensures a sustained influence on the inflammatory and nociceptive pathways.

How to Use Panodin-SR

Panodin-SR is an extended-release formulation of etodolac, administered by the oral route as a film-coated tablet. This formulation is specifically engineered for a once daily administration schedule.

---

Standard Administration and Dosing

The typical adult dosing for chronic conditions, such as Osteoarthritis and Rheumatoid Arthritis, is generally in the range of 400 mg to 1000 mg taken once a day. Dosing should be established using the lowest effective amount for symptomatic relief. For the extended-release product, dosages should not exceed a general maximum of 1000 mg per day. A patient's dosage should be reviewed and potentially adjusted after a therapeutic response is observed, which is typically around two weeks of continuous use. The tablet may be taken with or without food, as the presence of food does not significantly alter the total absorption of the active ingredient.

Procedural Requirements

The extended-release tablet must be swallowed whole to ensure the controlled-release mechanism functions as intended. Patients are explicitly instructed not to crush, break, or chew the tablet, as destroying the tablet's integrity may lead to an immediate release of the entire dose.

Population-Specific Dosing

For pediatric patients aged 6 to 16 years with Juvenile Rheumatoid Arthritis, dosing is weight-based, with prescribed doses ranging from 400 mg to 1000 mg once daily, depending on the patient's body weight. In older adults, no initial dose change is required based on the drug's pharmacokinetics; however, careful dose adjustment is necessary. For patients with mild-to-moderate renal dysfunction, no general dosage adjustment is necessary for this specific formulation.

Research evidence / Overview of studies for Panodin-SR

Evidence for Use in Osteoarthritis

The research into Panodin-SR (Etodolac) for Osteoarthritis primarily relies on short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time, often comparing the substance to a placebo or to other substances being studied. These studies monitored patient-reported outcomes describing perceived discomfort, focusing on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, such as the ability to move joints and complete daily activities. Research examined outcomes related to physical discomfort and daily functioning in adult patients with Osteoarthritis. Many trials reported measurements documenting changes in pain intensity scores and stiffness over the defined time intervals. Limited information for long-term outcomes exists, meaning evidence provides limited insight into the long-term maintenance of observed changes or influence on the condition's progression over time.

Evidence for Use in Rheumatoid Arthritis

Panodin-SR was evaluated in studies focused on symptomatic management for Rheumatoid Arthritis (RA). The evidence base includes short-term comparative trials where Etodolac was studied for symptoms against other existing treatments for RA. Studies monitored physiological strain or stress, particularly tracking changes in counts of tender and swollen joints and the overall functional status. Studies reported how symptoms evolved in the observed populations during the short trial periods. Comparative evidence is lacking for a full assessment against all modern therapeutic options. The current research does not determine whether an individual will respond similarly over many months or years due to limited follow-up durations.

Evidence for Acute Pain Management

Research exploring short-term symptom changes associated with Panodin-SR involves highly controlled, single-dose, placebo-controlled RCTs. Trials were structured to study outcomes describing episodic or acute changes, particularly evaluating the time to the start of activity and the total duration of observed changes in pain metrics after a single dose. Findings describe patterns related to the speed and length of the observed changes in pain metrics. The results apply only to the populations studied in these controlled research settings. Data are still emerging or remain scarce regarding the use of Etodolac for highly recurrent or diverse types of acute inflammatory pain.

Key Studies & References

1. Etodolac Extended-Release Tablets. NIH DailyMed (Official Labeling for FDA-approved drug products)

Common questions about Panodin-SR (FAQ)

---

Q: How quickly does Panodin-SR typically begin to work?

A: According to official clinical studies, a full therapeutic response for chronic conditions like arthritis is typically not observed right away. Noticeable improvement in symptoms is generally seen after approximately one to two weeks of continuous use of Panodin-SR.

Q: Can Panodin-SR cause stomach upset or nausea?

A: Yes, official regulatory documents list nausea and symptoms related to the stomach, such as abdominal pain, dyspepsia (indigestion), and general stomach upset, among the commonly documented adverse reactions associated with this medicine.

Q: Are there any over-the-counter medicines that interact with Panodin-SR?

A: Official materials specifically warn that Panodin-SR may interact with other pain relievers. Co-administration with other Non-steroidal anti-inflammatory drugs (NSAIDs), including over-the-counter Aspirin, is generally contraindicated if a patient has a history of allergic-type reactions to those substances.

Q: Do research studies show that Panodin-SR works differently for different groups of people?

A: Official prescribing information indicates that for pediatric patients, dosing is calculated based on body weight. Additionally, while older adults (over 65) do not typically require a dosage change, regulatory documents note that this population is at greater risk for serious gastrointestinal and renal adverse events.

Q: Does taking Panodin-SR require any specific dietary restrictions?

A: Official patient information states that the medicine may be taken with or without food. However, patients are generally advised in official materials to avoid alcohol while using this medicine, as alcohol may increase the risk of serious stomach bleeding.

Q: What happens if someone accidentally takes too much Panodin-SR?

A: The documented signs of acute overdose in official materials may include lethargy, drowsiness, nausea, vomiting, and pain in the upper stomach area. Information about overdose is presented in regulatory materials because it is a condition that requires immediate attention.

Q: Can Panodin-SR be used long-term?

A: Official labeling permits long-term use for its approved chronic conditions. However, the regulatory safety profile consistently notes that the risk of serious cardiovascular events (like heart attack or stroke) and serious gastrointestinal events increases with a longer duration of use.

Q: Can I take Panodin-SR if I have a history of kidney problems?

A: Official regulatory materials state that this medicine is not recommended for use in patients with severe renal impairment (severe kidney problems). Official guidance is specific to severe renal impairment; information regarding less severe conditions is not covered in detail in the general label.

Q: Is Panodin-SR safe to take if I have liver disease?

A: Official regulatory materials state that this medicine is not recommended for use in patients with severe hepatic failure (severe liver failure).

Q: What should I do if I forget to take my scheduled dose of Panodin-SR?

A: If a dose is missed, regulatory patient information states to take it as soon as possible, unless it is almost time for the next scheduled dose. If it is nearly time for the next dose, the missed dose should be skipped entirely. Regulatory patient information states that a double or extra dose should not be taken.

Q: Does stopping Panodin-SR suddenly cause withdrawal symptoms?

A: Panodin-SR is classified as a Non-steroidal anti-inflammatory drug (NSAID) and is not designated as a controlled substance by regulatory bodies. Official labeling and classification do not indicate a potential for physical dependence or withdrawal symptoms associated with its use.

Q: Is it normal to feel a mild headache when starting Panodin-SR?

A: Yes, official regulatory documents list headache among the commonly documented adverse reactions associated with the use of this medicine. It is considered one of the more frequently reported side effects.

Q: What kind of studies or research support the use of Panodin-SR?

A: Research supporting the approved uses of Panodin-SR primarily consists of short-term, randomized controlled trials (RCTs). These studies examined patient-reported outcomes for physical discomfort and functional status in patients with Osteoarthritis and Rheumatoid Arthritis.

Q: What is the difference between an immediate-release and a sustained-release formulation?

A: The immediate-release (IR) formulation is designed to release the entire active substance quickly, resulting in a higher, faster peak concentration in the body. The sustained-release (SR) formulation is engineered to release the substance slowly and consistently over an extended duration, which helps maintain a more stable concentration over time.

Q: Is there a risk of weight gain while using Panodin-SR?

A: Official adverse reaction lists do not specify weight gain as a common effect. However, unusual weight gain is listed in safety warnings as a potential symptom of fluid retention (edema) or heart failure, which are serious conditions noted in the safety warnings for this class of medicine.

Q: Are there any warning signs I should look for when starting Panodin-SR?

A: Official materials describe warning signs associated with serious events, such as symptoms that may indicate cardiovascular events (e.g., chest pain, sudden weakness), gastrointestinal bleeding (e.g., black or tarry stools), and severe allergic reactions (e.g., difficulty breathing or rash).

Q: Does Panodin-SR have the potential for misuse or dependence?

A: Panodin-SR is a Non-steroidal anti-inflammatory drug (NSAID). Official regulatory classification and labeling do not indicate a potential for misuse or physical dependence, unlike controlled substances such as narcotic pain medicines.

Q: Can I drive or operate machinery while taking Panodin-SR?

A: Official product information notes that adverse reactions such as dizziness and headache are commonly documented. Patients experiencing these or other Central Nervous System (CNS) effects are generally advised that their ability to drive or operate machinery may be affected.

Q: Is there a generic version of Panodin-SR available?

A: Yes, the active ingredient in Panodin-SR, Etodolac, is generally available as a generic medicine in various forms, according to regulatory documentation.

Q: Are there any lifestyle changes recommended when using Panodin-SR?

A: Official patient information advises patients to avoid alcohol and smoking tobacco while using this medicine. This is because co-use may increase the risk of serious gastrointestinal adverse events, specifically including bleeding.

Q: What should be avoided when taking Panodin-SR?

A: According to regulatory information, patients must avoid use after Coronary Artery Bypass Graft (CABG) surgery and use by those with a history of allergic-type reactions to aspirin or other NSAIDs. Additionally, the use of alcohol should be avoided due to the increased risk of gastrointestinal bleeding.

Q: Why is Panodin-SR called a 'sustained-release' product?

A: It is called 'sustained-release' because the medicine is engineered to release the active substance, Etodolac, slowly and consistently over an extended duration of time. This differs from immediate-release forms which release the substance all at once.

Q: Does Panodin-SR have any specific monitoring requirements, like blood tests?

A: For patients using this medicine for a prolonged period, official guidance advises that blood work may be required for monitoring purposes. This testing is typically used to check for potential adverse effects on kidney and liver function.

Q: Can Panodin-SR affect mood or cause emotional changes?

A: Official adverse event documentation notes reports of mental or mood changes and depression associated with the use of this medicine.

Storage Conditions

Panodin-SR (Etodolac Sustained-Release Tablets) must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and excessive heat. To maintain product integrity, the tablets must be stored in their original container and the bottle kept tightly closed.

Child Safety and Handling

In accordance with regulatory mandates, the medication must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Panodin-SR should be discarded by taking it to an authorized drug take-back program or collection point. It is strictly instructed that the tablets must not be flushed down a toilet or poured into a drain to prevent environmental contamination.